Save Product
Product Details
Synonyms
OX40L, TNFSF4, CD252, Glycoprotein Gp34, TXGP1, CD134 ligand, CD134L
Source
Rat OX40 Ligand, His Tag (OXL-R5248) is expressed from human 293 cells (HEK293). It contains AA Gln 49 - Leu 199 (Accession # Q9Z2P3-1).
Predicted N-terminus: His
Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 53.8 kDa. The protein migrates as 58-68 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Rat OX40 Ligand, His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Rat OX40 Ligand, His Tag (Cat. No. OXL-R5248) is more than 85% and the molecular weight of this protein is around 55-70 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Rat OX40, Fc Tag (Cat. No. OX0-R5253) at 2 μg/mL (100 μL/well) can bind Rat OX40 Ligand, His Tag (Cat. No. OXL-R5248) with a linear range of 20-78 ng/mL (QC tested).
Protocol
Immobilized Rat OX40 Ligand, His Tag (Cat. No. OXL-R5248) at 2 μg/mL (100 μL/well) can bind Rat OX40, Fc Tag (Cat. No. OX0-R5253) with a linear range of 0.2-5 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor ligand superfamily member 4
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
13 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
